Provided by Tiger Trade Technology Pte. Ltd.

Perspective Therapeutics

4.60
-0.2600-5.35%
Volume:2.01M
Turnover:9.20M
Market Cap:524.40M
PE:-3.29
High:4.92
Open:4.80
Low:4.37
Close:4.86
52wk High:6.16
52wk Low:1.60
Shares:114.00M
Float Shares:102.00M
Volume Ratio:1.53
T/O Rate:1.97%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3971
EPS(LYR):-1.2306
ROE:-41.65%
ROA:-23.35%
PB:2.53
PE(LYR):-3.74

Loading ...

Perspective Therapeutics Reports Promising Q3 2025 Results

TIPRANKS
·
Nov 11, 2025

Perspective Therapeutics Q3 net loss widens to $26 mln

Reuters
·
Nov 11, 2025

Perspective Therapeutics Q3 EPS $(0.35) Misses $(0.33) Estimate, Sales $209.000K Miss $223.833K Estimate

Benzinga
·
Nov 11, 2025

BRIEF-Perspective Therapeutics Q3 EPS USD -0.35

Reuters
·
Nov 11, 2025

Press Release: Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results

Dow Jones
·
Nov 11, 2025

Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX) and Perspective Therapeutics (CATX)

TIPRANKS
·
Nov 04, 2025

Perspective Therapeutics Updates Executive Compensation and Change-in-Control Terms

Reuters
·
Nov 04, 2025

Perspective Therapeutics to Join UBS Global Healthcare Conference

Reuters
·
Oct 31, 2025

Perspective Therapeutics Advances in Neuroendocrine Tumor Therapy with Promising Clinical Study

TIPRANKS
·
Oct 28, 2025

Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results

GlobeNewswire
·
Oct 24, 2025

Do Investors Expect Too Much From CATX as [212Pb]VMT-α-NET Shows Promising but Mixed Results?

Simply Wall St.
·
Oct 23, 2025

Positive Outlook on Perspective Therapeutics Amidst Challenges: Buy Rating Reiterated with $14 Target

TIPRANKS
·
Oct 21, 2025

Perspective Therapeutics Shares Fall After Cancer Drug Study Interim Data

Dow Jones
·
Oct 21, 2025

Perspective Therapeutics falls after update on Phase 1/2a trial

TIPRANKS
·
Oct 21, 2025

Perspective Therapeutics (CATX) Gets a Buy from Oppenheimer

TIPRANKS
·
Oct 20, 2025

Perspective Therapeutics Reports Positive Interim Results for [212Pb]VMT-α-NET in Neuroendocrine Tumor Trial

Reuters
·
Oct 20, 2025

Analysts Offer Insights on Healthcare Companies: Taysha Gene Therapies (TSHA), Artiva Biotherapeutics, Inc. (ARTV) and Perspective Therapeutics (CATX)

TIPRANKS
·
Oct 17, 2025

Bank of America Securities Sticks to Their Hold Rating for Perspective Therapeutics (CATX)

TIPRANKS
·
Oct 14, 2025

Perspective Therapeutics Price Target Maintained With a $14.00/Share by BTIG

Dow Jones
·
Oct 13, 2025

Perspective Therapeutics Inc : Btig Initiates Coverage With Buy Rating: Target Price $14

THOMSON REUTERS
·
Oct 10, 2025